REFERENCES
- Alving, C. R., Steck, E. A., Chapman, W. L., Waits, V. B., Hendricks, L. S., Swartz, G. M. & Hanson, W. L. (1978). Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proceedings of the National Academy of Sciences of the United States of America, 75, 2959–2963.
- Baillie, A. J., Dolan, T.F., Alexander, J. & Carter, K.C. (1989). Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. International Journal of Pharmaceutics, 57, 23–28.
- Berman, J. D., Gallalee, J. F. & Gallalee, J. V. (1988). Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. American Journal of Tropical Medicine and Hygiene, 39, 41–45.
- Black, C. D. V., Watson, G. J. & Ward, R. J. (1977). The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 71, 550–552.
- Bradley, D. J. & Kirkley, J. (1977). Regulation of Leishmania populations within the host I. The variable course of Leishmania donovani infections in mice. Clinical and Experimental Immunology, 30, 119–129.
- Carter, K. C., Baillie, A. J., Alexander, J. & Dolan, T. F. (1988). The therapeutic effects of sodium stibogluconate in the BALB/c mouse infected with Leishmania donovani is organ dependent. Journal of Pharmacy and Pharmacology, 40, 370–373.
- Carter, K. C., Dolan, T. F., Alexander, J., Baillie, A. J. & McColgan, C. (1989). Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the liver, spleen, and bone marrow in Leishmania donovani infected BALB/c mice. Journal of Pharmacy and Pharmacology, 41, 87–91.
- Chulay, J. D., Fleckenstein, L. & Smith, D. H. (1988). Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 69–72.
- Chulay, J. D., Spencer, H. C. & Mugambi, M. (1985). Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). American Journal of Tropical Medicine and Hygiene, 34, 702–709.
- Gellhorn, A. & Van Dyke, H. B. (1946). The correlation between distribution of antimony and chemotherapeutic effect in experimental leishmaniasis. Journal of Pharmacology and Experimental Therapeutics, 88, 162–172.
- Murray, H. W., Berman, J. D. & Wright, S. D. (1988). Immunochemotherapy for intracellular Leishmania donovani infection: inferferon γ plus pentavalent antimony. Journal of Infectious Diseases, 157, 973–978.
- Rees, P. H., Keating, M. I., Kager, P. A. & Hockmeyer, W. T. (1980). Renal clearance of pentavalent antimony-sodium stibogluconate. Lancet, ii, 226–229.
- Ward, R. J., Black, C. D. V. & Watson, G. J. (1979). Determination of antimony in biological materials by electrothermal atomic absorption spectroscopy. Clinica Chimica Acta, 99, 143–152.
- Wickramasinghe, S. N., Abdalla, S. H. & Kaisili, E. G. (1987). Ultrastructure of bone marrow in patients with visceral leishmaniasis. Journal of Clinical Pathology, 40, 267–275.
- World Health Organization (1984). The Leishmaniases. Technical Report Series No. 701. Geneva: World Health Organization.